Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia

Hemoglobin Levels Rose and were Maintained in Therapeutic Range ErepoXen was Generally Well Tolerated With No Significant Treatment-related Adverse Events Compound uses Patented PolyXen® Technology for Recombinant Erythropoietin LEXINGTON, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc...

New York, 14/07/2015 (informazione.news - comunicati stampa - varie)
Copyright GlobeNewswire


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire